LUCD Lucid Diagnostics, Inc. Expected Profit

Expected net profit figures reflect the momentum of Lucid Diagnostics Inc. (LUCD), an innovator in esophageal cancer diagnostics that has streamlined screening through AI. The value of serves as the current metric for this trajectory. The unique EsoGuard DNA test creates a significant barrier to entry for laboratories due to its patents. The startup is currently scaling sales, focusing on integrating the product into insurance policies.

LUCD - Lucid Diagnostics Inc. Expected Net Profit over the range 07/04/2022 - 11/15/2026

LUCD (Lucid Diagnostics, Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:

Stock Price luciddx.com|LUCD - Analyst Consensus Forecast

- market capitalization data:

Market Value Lucid Diagnostics, Inc.|LUCD - Total Company Value

- company book value details:

Accounting Value per Share Lucid Diagnostics|LUCD - Total Stockholders' Equity|Market Value to Book Value Ratio luciddx.com|LUCD - Company Total Asset Base

- debt and solvency information:

- earnings and market ratios statistics:

LUCD - Net Income|Projected Future Earnings Lucid Diagnostics Inc.|LUCD - Business Payback Period|Forward P/E Multiple Lucid Diagnostics Inc.|LUCD - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Lucid Diagnostics Inc|LUCD - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Lucid Diagnostics|LUCD - Earnings per share for the last 12 months|Quarterly EPS earnings growth luciddx.com|LUCD - Expected net earnings per share growth this year|Earnings growth forecast for next year Lucid Diagnostics Inc.

- total revenue and sales volume data:

LUCD - Revenue and Sales Volume|Projected Sales Volume luciddx.com|LUCD - Price-to-Revenue Multiple|Price-to-Projected Revenue Ratio Lucid Diagnostics, Inc

Initial company analysis:LUCD, Lucid Diagnostics

Finished products of Lucid Diagnostics Inc

This indicator aggregates projected net income, reflecting the discounted value of future cash flows to determine the asset's fair value. Analyzing the expected income level allows for an assessment of the EsoGuard operating leverage's impact on the capitalization of Lucid Diagnostics Inc. (LUCD), where the scaling of centralized testing should offset current high promotion costs within the medical community.

Key competitors